Mereo BioPharma Group (STU:MAH0) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:MAH0 Mereo BioPharma Group PLC STU:MAH0
36 GF Score
Price €0.28
! 1 Warning Sign
View Full Analysis

What is Mereo BioPharma Group FFO per Share?

FFO per Share only applies to REITs.

STU:MAH0
36GF Score
Mereo BioPharma Group PLC STU:MAH0
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mereo BioPharma Group Business Description

Other Exchanges MREO:USA0A9G:UK
Address One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
36GF Score

Get the complete analysis for STU:MAH0

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.28
Price